Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon α2b and ribavirin: An open-label series

Transplantation

Volumn 77, Issue 2, 2004, Pages 190-194

  Rodriguez Luna, Hector ^a   Khatib, Amer ^a   Sharma, Pratima ^a   De Petris, Giovanni ^b   Williams, James W ^b   Ortiz, Jose ^a   Hansen, Kathleen ^a   Mulligan, David ^a   Moss, Adyr ^a   Douglas, David D ^a   Balan, Vijayan ^a   Rakela, Jorge ^a   Vargas, Hugo E ^a,c  

^a Division of Transplantation Medicine   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; RAPAMYCIN; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; STEROID; TACROLIMUS; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; BONE MARROW DEPRESSION; CHOLESTATIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENOTYPE; GRAFT REJECTION; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER BIOPSY; LIVER FIBROSIS; LIVER NECROSIS; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; RECURRENT INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON ALFA-2A; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 10744233319     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000100481.14514.BB     Document Type: Article

References (30)

1. Wong JB, McQuillan GM, McHutchison JG, et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90(10): 1562.
2. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28(3): 823.
3. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334(13): 815.
4. Feray C, Gigou M, Samuel D, et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994; 20(5): 1137.
5. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32(4 Pt 1): 852.
6. Sanchez-Fueyo A, Restrepo JC, Quinto L, et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002; 73(1): 56.
7. Gane E. Treatment of recurrent hepatitis C. Liver Transpl 2002; 8(10 suppl 1): S28.
8. Bodenheimer HC Jr, Lindsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26(2): 473.
9. Feray C, Samuel D, Gigou M, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995; 22(4 Pt 1): 1084.
10. Gane EJ, Lo SK, Riordan SM, et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998; 27(5): 1403.
11. Lavezzo B, Franchello A, Smedile A, et al. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin. J Hepatol 2002; 37(2): 247.
12. Shakil AO, McGuire B, Crippin J, et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002; 36(5): 1253.
13. Alberti AB, Belli LS, Airoldi A, et al. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study. Liver Transpl 2001; 7(10): 870.
14. Narayanan-Menon K, Poterucha J, El-Amin O, et al. Treatment of posttransplantation recurrence of hepatitis c with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transplant 2002; 8(7): 623.
15. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347(13): 975.
16. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358(9286): 958.
17. Vogel W, Ferenci P, Fontana RJ, et al. Peginterferon alfa-2A (40kD) (Pegasys) in liver transplant recipients with established recurrent hepatitis C: interim results of an ongoing randomize multicenter trial. Hepatology 2002; 36(4 Pt 2): 312A.
18. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22(6): 696.
19. Everhart JE, Wei Y, Eng H, et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology 1999; 29(4): 1220.
20. Feray C, Caccamo L, Alexander GJ, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999; 117(3): 619.
21. Wright TL, Combs C, Kim M, et al. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994; 20(4 Pt 1): 773.
22. Singh N, Gayowski T, Wannstedt CF, et al. Interferon-alpha therapy for hepatitis C virus recurrence after liver transplantation: long-term response with maintenance therapy. Clin Transplant 1996; 10(4): 348.
23. Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25(5): 591.
24. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339(21): 1485.
25. Bizollon T, Palazzo U, Ducerf C, et al. Pilot, study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26(2): 500.
26. Samuel D, Bizollon T, Feray C, et al. Combination of interferon alfa 2b plus ribavirin for recurrent HCV infection after liver transplantation: a ramdomised controlled study. Hepatology [abstract] 2000; 32: 395A.
27. Rostaing L, Modesto A, Baron E, et al. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74(3): 512.
28. Magnone M, Holley JL, Shapiro R, et al. Interferon-alpha-induced acute renal allograft rejection. Transplantation 1995; 59(7): 1068.
29. Kramer P, ten Kate FW, Bijnen AB, et al. Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1984; 1(8384): 989.
30. Feray C, Samuel D, Thiers V, et al. Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest 1992; 89(4): 1361.